Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

69 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Third-line chemotherapy in advanced biliary cancers (ABC): pattern of care, treatment outcome and prognostic factors from a multicenter study.
Salati M, Rizzo A, Merz V, Messina C, Francesco C, Gelsomino F, Spallanzani A, Ricci AD, Palloni A, Frega G, De Lorenzo S, Carotenuto P, Pettorelli E, Benatti S, Luppi G, Melisi D, Brandi G, Dominici M. Salati M, et al. Among authors: merz v. Expert Rev Gastroenterol Hepatol. 2022 Jan;16(1):73-79. doi: 10.1080/17474124.2022.2017772. Epub 2021 Dec 21. Expert Rev Gastroenterol Hepatol. 2022. PMID: 34890512
Angiopoietin-Like Proteins in Angiogenesis, Inflammation and Cancer.
Carbone C, Piro G, Merz V, Simionato F, Santoro R, Zecchetto C, Tortora G, Melisi D. Carbone C, et al. Among authors: merz v. Int J Mol Sci. 2018 Feb 1;19(2):431. doi: 10.3390/ijms19020431. Int J Mol Sci. 2018. PMID: 29389861 Free PMC article. Review.
Outcomes of Primary Chemotherapy for Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma.
Maggino L, Malleo G, Marchegiani G, Viviani E, Nessi C, Ciprani D, Esposito A, Landoni L, Casetti L, Tuveri M, Paiella S, Casciani F, Sereni E, Binco A, Bonamini D, Secchettin E, Auriemma A, Merz V, Simionato F, Zecchetto C, D'Onofrio M, Melisi D, Bassi C, Salvia R. Maggino L, et al. Among authors: merz v. JAMA Surg. 2019 Oct 1;154(10):932-942. doi: 10.1001/jamasurg.2019.2277. JAMA Surg. 2019. PMID: 31339530 Free PMC article.
Population pharmacokinetics and exposure-overall survival analysis of the transforming growth factor-β inhibitor galunisertib in patients with pancreatic cancer.
Gueorguieva I, Tabernero J, Melisi D, Macarulla T, Merz V, Waterhouse TH, Miles C, Lahn MM, Cleverly A, Benhadji KA. Gueorguieva I, et al. Among authors: merz v. Cancer Chemother Pharmacol. 2019 Nov;84(5):1003-1015. doi: 10.1007/s00280-019-03931-1. Epub 2019 Sep 3. Cancer Chemother Pharmacol. 2019. PMID: 31482224
Plasma IL8 Is a Biomarker for TAK1 Activation and Predicts Resistance to Nanoliposomal Irinotecan in Patients with Gemcitabine-Refractory Pancreatic Cancer.
Merz V, Zecchetto C, Santoro R, Simionato F, Sabbadini F, Mangiameli D, Piro G, Cavaliere A, Deiana M, Valenti MT, Bazan D, Fedele V, Lonardi S, Melisi D. Merz V, et al. Clin Cancer Res. 2020 Sep 1;26(17):4661-4669. doi: 10.1158/1078-0432.CCR-20-0395. Epub 2020 Jun 12. Clin Cancer Res. 2020. PMID: 32532788 Clinical Trial.
69 results